{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:41:26Z","timestamp":1774460486101,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672271"],"award-info":[{"award-number":["81672271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1311902"],"award-info":[{"award-number":["2018YFC1311902"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017378","name":"Shanghai Key Discipline for Respiratory Diseases","doi-asserted-by":"publisher","award":["2017ZZ02014"],"award-info":[{"award-number":["2017ZZ02014"]}],"id":[{"id":"10.13039\/100017378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113140","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T15:25:27Z","timestamp":1727105127000},"page":"113140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"PB","title":["The predict factors and clinical prognosis value of immune-related pneumonia of receiving PD-1 inhibitor in advanced non-small cell lung cancer: A retrospective study"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8698-2047","authenticated-orcid":false,"given":"Jin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengchen","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangran","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beli","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0724-6359","authenticated-orcid":false,"given":"Yi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2024.113140_b0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"10299","key":"10.1016\/j.intimp.2024.113140_b0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113140_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-09003-z","article-title":"Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis","volume":"21","author":"Ngamphaiboon","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.113140_b0020","first-page":"181","article-title":"Immunotherapy-induced airway disease: a new pattern of lung toxicity of immune checkpoint inhibitors. Respiration","volume":"99","author":"Mitropoulou","year":"2020","journal-title":"Int. Rev. Thorac. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2024.113140_b0025","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.intimp.2024.113140_b0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1115","key":"10.1016\/j.intimp.2024.113140_b0035","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200409","article-title":"Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers","volume":"93","author":"Nobashi","year":"2020","journal-title":"Br. J. Radiol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113140_b0040","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113140_b0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000503566","article-title":"Landscape of immune-related pneumonitis in cancer patients with asthma being treated with immune checkpoint blockade","volume":"98","author":"Galant-Swafford","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.intimp.2024.113140_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113140_b0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.113140_b0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","article-title":"Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors","volume":"20","author":"Fukihara","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.intimp.2024.113140_b0065","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920922033","article-title":"Association of immune-related pneumonitis with the efficacy of PD-1\/PD-L1 inhibitors in non-small cell lung cancer","volume":"12","author":"Cui","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113140_b0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The eighth edition lung cancer stage classification","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2024.113140_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.638312","article-title":"Inflammatory markers predict survival in patients with advanced gastric and colorectal cancers receiving anti-PD-1 therapy","volume":"9","author":"Fan","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2024.113140_b0080","article-title":"CD8(+) lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors","author":"Takahashi","year":"2022","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.113140_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2024.113140_b0090","article-title":"Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.113140_b0095","article-title":"Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113140_b0100","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-00920-z","article-title":"Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond","volume":"22","author":"Reuss","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.intimp.2024.113140_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint inhibitor pneumonitis induced by anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113140_b0110","article-title":"Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113140_b0115","unstructured":"P. Binfield, At PLoS ONE we're batty about bats, PLoS: Public Library of Science, 2008, Web log message."},{"issue":"8","key":"10.1016\/j.intimp.2024.113140_b0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/intimm\/dxaa022","article-title":"Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease","volume":"32","author":"Suzuki","year":"2020","journal-title":"Int. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113140_b0125","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2024.113140_b0130","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.42406","article-title":"Early increase of circulating transitional B cells and autoantibodies to joint-related proteins in patients with metastatic melanoma developing checkpoint inhibitor-induced inflammatory arthritis","volume":"75","author":"Gatto","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113140_b0135","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.113140_b0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","article-title":"Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"150","author":"Chu","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113140_b0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","article-title":"IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer","volume":"41","author":"Blomberg","year":"2023","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.intimp.2024.113140_b0150","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/1759-7714.13187","article-title":"High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer","volume":"10","author":"Tone","year":"2019","journal-title":"Thorac. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924016618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924016618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:56:16Z","timestamp":1734069376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924016618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"alternative-id":["S1567576924016618"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113140","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The predict factors and clinical prognosis value of immune-related pneumonia of receiving PD-1 inhibitor in advanced non-small cell lung cancer: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113140"}}